Expertise Partner & Mastermind Partner

Our unique perspectives, built from decades of scientific expertise and precision delivery of the largest volume of drug development data in the world, helps our clients identify new approaches and anticipate tomorrow’s challenges as they evolve. Driven by a passion for excellence and a relentless commitment to quality, we unlock opportunities that advance innovation and deliver on the promise of a healthier world.





Expertise Partner

ANGLE’s Parsortix technology enables the capture and harvest of circulating tumor cells from patient blood. The resulting liquid biopsy (simple blood test) provides a powerful tool to deliver personalized cancer care. ANGLE is currently developing its first diagnostic product in the area of ovarian cancer. The Parsortix system has CE Mark regulatory approval in Europe and an FDA approval process is underway in the US.



Expertise Partner

MolecularMD develops and commercializes specialty diagnostics for oncology applications. Tests are designed to allow appropriate selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. MolecularMD integrates proven and innovative platform technologies with clinical assay design, validation, and centralized testing to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. MolecularMD’s core competency is in streamlining the development, regulatory approval, and clinical deployment of precision oncology medicines. The company provides customized Clinical Trial Assay and CDx development in their CAP-accredited, CLIA-certified laboratories in Portland, Oregon and Cambridge, Massachusetts.



Expertise Partner

Guardant Health is a pioneer in non-invasive cancer diagnostics, addressing challenges across the cancer care continuum. The company has raised more than $200 million from leading venture capital firms and in 2014 launched Guardant360, the first comprehensive liquid biopsy for clinical use. Guardant Health is improving therapy selection for advanced cancer patients across the globe using its proprietary cell-free circulating tumor DNA NGS platform. Guardant Health is partnered with biopharmaceutical companies to prospectively screen patients for trial enrollment, develop companion diagnostics to support clinical adoption, and use retrospective analysis for early insights into patient response and tumor evolution, as well as accelerate the development of new therapies.



Expertise Partner

NeoGenomics is a premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic and predictive testing. Our vision embodies uncompromising quality, exceptional service, and innovative solutions. We have a network of CAP-accredited, CLIA-licensed facilities across the U.S., but work hard to maintain easy access and all the efficiencies of a smaller operation.



Expertise Partner & Mastermind Partner

Diaceutics is the diagnostic development and commercialization service provider. We have been leading this field for 13 years, entirely focused on the intersection between diagnostics and therapeutic decision making. We provide an end to end service that encompasses everything from understanding the diagnostic landscape to test implementation in treatment pathways. This is all enabled by a robust flow of data from our global laboratory network. Our ultimate goal is to drive better testing to enable better treatment decisions for patients.



Expertise Partner

Q2 Solutions is a leading global clinical trials laboratory services organization that partners with biopharmaceutical, medical device and diagnostics customers to transform science and data into actionable medical insights. Its laboratory services span the development lifecycle from Discovery through Clinical Trials to Commercialization that includes predictive biomarker solutions for Companion Diagnostics.



Expertise Partner

Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world’s largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.



Exhibitor Partner

Almac Diagnostics is a stratified medicine company specialising in biomarker driven clinical trials. Our diagnostic experience spans oncology, immunology, CNS and infective diseases. Our global laboratories, based in the UK and US offer tailored solutions from discovery to commercialisation: Biomarker discovery. Custom assay development & validation. DNA and RNA panel solutions. Flexible CDx development & commercialisation. Expert regulatory support. Bioinformatics & software development. Your Clinical Trial Diagnostic Partner.


logo (1)

Meeting Partner

• Epic Sciences’ circulating tumor cell (CTC) platform can assist in stratifying patient populations in either observational or interventional studies with an emphasis on prostate and breast cancer.
• Our platform has the ability to conduct multi-parametric single cell analysis of protein expression, cell morphology and single cell genomics to see the widest biological range of cells with unmatched sensitivity.
• Epic Sciences works with investigators at cancer centers and pharmaceutical companies to bring functional cell profiling techniques to pair rare cell types, both genotypically and phenotypically, with outcomes.



Program Partner

Corgenix is a global diagnostics company that commercializes Immunoassay IVDs for autoimmune, cardiovascular and liver diseases. Additionally, Corgenix has more than 20 years’ experience in contract Immunoassay development and manufacturing, serving the needs of Pharma and Diagnostic companies. Our Personalized Diagnostics Team collaborates with Pharma and other Personalized Medicine stakeholders to develop and commercialize companion diagnostics. Our newly established CLIA laboratory allows for better management of the assay development process and provides more options for our Partners.



Program Partner

Biocartis aims to provide direct access to personalized medicine for patients worldwide by developing fully integrated and broadly applicable molecular diagnostics. Our platforms can be used in a wide variety of healthcare settings to enable rapid and high-quality care close to patients.



Program Partner

Ultivue is a venture-backed company developing reagent-driven solutions for high-performance biological imaging in situ, combining unlimited multiplexing at high speed with high spatial resolution. Ultivue’s proprietary solutions will enable researchers to realize the promise of personalized medicine. The company has launched products and services that will seamlessly integrate into existing workflows for biomarker discovery, assay validation, and companion diagnostic applications.



Program Partner

Unilabs is a leader in Companion Diagnostic testing in Europe with several years of experience with the associated necessary global, customized logistics & regulatory know-how. Unilabs is Serving Pharma as a highly customer centric and specialized bioanalytical laboratory service partner with structured processes to reduce budget risks & stalling of drug development.Unilabs has more than 8.000 employees, and more than 30 years of clinical trials experience, handling more than 3.000 studies involving a broad range of matrices from numerous species and in a vast number of therapeutic areas.



Program Partner

Enabling higher multiplexing for real-time PCR instruments. Leveraging digital signal processing to provide higher efficiency and lower costs for our laboratory customers. ChromaCode is deploying a disruptive solution for mid-density, multiplexed analysis, high-definition PCR or HDPCR​ , exclusively licensed from the California Institute of Technology.



Program Partner

Invivoscribe is the worldwide leader in precision medicine and companion diagnostics (CDx) for hematological malignancies. Invivoscribe offers a full range of hematology-oncology testing products and services (B- and T-cell clonality, NGS gene panels, MRD assays, and comprehensive bioinformatics software), all developed under ISO 13485 design control and manufactured in our own cGMP facility. We also operate the Laboratories for Personalized Molecular Medicine (LabPMM), a global network of clinical reference labs with locations in the United States, Germany, and Japan. These laboratories offer an ever-expanding menu of internationally harmonized tests to support the stratification and enrollment of patients in clinical trials, optimized treatments, and development of CDx. We continually strive to provide access to accurate test results and improve the quality of healthcare worldwide.



Program Partner

Leica Biosystems is a global leader in workflow solutions and automation, integrating each step in the workflow. As the only company to own the workflow from biopsy to diagnosis, we are uniquely positioned to break down the barriers between each of these steps. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. In line with our Mission, we have established the following challenge for ourselves: Enable patients to get their diagnosis within 24 hours from biopsy. This is a goal we are striving towards, a goal that will guide our future strategies. This vision aims to decrease the time it takes from biopsy to patient diagnosis, to a 24 hour period. With a presence in every step of the workflow, no other company is positioned to streamline all these steps so that the whole process takes less than 24 hours.



Program Partner

Sysmex Inostics, a subsidiary of Sysmex Corporation, is a leader in blood-based molecular diagnostics testing in oncology. Our highly sensitive OncoBEAM™ kits and tests offer a minimally-invasive alternative for the detection of cancer gene mutations, clinical trials testing and companion diagnostics development.



Program Partner

Accelerate your next breakthrough in diagnostics and therapeutics. Abcam’s comprehensive portfolio of high quality, customizable solutions are ideal for diagnostic and therapeutic applications. Our technical ability coupled with a flexible commercial approach enables us to deliver projects that will help achieve your goals



Program Partner

Biodesix® is an experienced partner in the field of blood-based molecular diagnostic testing. Our comprehensive diagnostic testing capabilities help our partners decipher the complexity of cancer by interpreting genomic and proteomic information from both tumor biology and the patient’s immune response. Biodesix enables our partners throughout the discovery, development and commercialization of personalized diagnostics to support new therapies with companion diagnostic strategiess.



Program Partner & Panel Partner

Diagnostic certainty for every patient is a critical first step in the fight against cancer. Agilent’s Dako pathology solutions are designed to help hospitals and pathology laboratories around the world make fast and accurate diagnoses. This enables the most effective treatment decisions for cancer patients, ultimately improving patient care and enhancing survival rates.


logo-horizontal (3)

Program Partner

As an expert in immune biomarkers, HalioDx goal is to play a leading role in partnering with academic and pharmaceutical industry to leverage the immune contexture concept and deliver practical routine diagnostic tools to significantly impact therapy prescription for the benefit of patients. By precisely measuring the immune reaction in and around the tumor, HalioDx first tests already allow clinicians to determine the degree of severity of a patient’s disease and predict the response to treatment, regardless of the cancer stage or the molecular class..


Program Partner

PathAI is a leading provider of AI-powered research tools and services for pathology. PathAI’s platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning. Based in Boston, PathAI works with leading life sciences companies and researchers to advance precision medicine. To learn more, visit www.pathai.com.


Program Partner

Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. We support precision medicine from translational research to the development of companion diagnostics with innovative technologies and service through our Thermo Scientific, Applied Biosystems, Invitrogen, Gibco and Ion Torrent brands.


Boston Healthcare Associates-Logo-High Res

Program Partner

Boston Healthcare is a global consulting firm focused on enabling companies to derive optimal value from innovative products and services that have the potential to transform standards of care and significantly improve health outcomes. We have aligned our services and expertise to assure that the innovators reshaping healthcare are rewarded for their efforts and commitment, and we tailor our approach to the product and specific characteristics of each geographic market.


Program Partner


Roche for website

Program Partner



Panel Partner

We improve patient lives by unlocking the tissue phenome. Our work model builds on a simple premise: Tissue Phenomics strengthens results, from biomarker discovery to clinical development and meaningful diagnostics. We bring Tissue Phenomics to you, seamlessly integrate into your processes, and act as your reliable, science-driven partner along the way.



Panel Partner

Cofactor Genomics, Inc. is a translational and clinical assay company using RNA as the foundation for providing a better understanding of disease. We’ve invested in the development of proprietary databases focused on (1) cancer-specific gene expression and (2) unique immune cell RNA expression fingerprints. These databases enable us to quantify complex molecular profiles, and provide comprehensive characterization of immune response in all solid tumor tissues. Cofactor leverages our expertise in high-throughput sequencing, CAP-accredited laboratory, and unique machine-learning algorithms to deliver candidate biomarkers in an easy-to-interpret report.


download (1)

Panel Partner

Personal Genome Diagnostics (PGDx) advances the frontiers of cancer medicine through innovative genomic technologies for oncology researchers, drug developers, clinicians and patients. The expert team at PGDx draws on a deep understanding of cancer biology and extensive experience in cancer genomics and clinical oncology to pioneer genomic methods. These novel technologies precisely identify and characterize unique genomic alterations in tumors.



Spotlight Partner

Flagship Biosciences helps drug developers confidently define their path to success. Our Computational Tissue Analysis (cTA™) platform provides the quantitative, contextual tissue interpretation necessary to make timely decisions.

With a unique combination of our technology platform, extensive expertise across multiple disciplines (e.g., pathology, biology, image analysis, software engineering), and an in-house CLIA lab, Flagship Biosciences develops quantitative tissue biomarker interpretations for clinical development of tissue-based diagnostics, including companion diagnostics (CDx). We collaborate with biopharmaceutical teams at every stage of the clinical trial to:

  • Make informed pipeline decisions that will accelerate the right clinical path
  • Enable critical go/no go decisions based on confirmation of action
  • Design, implement and evaluate prototype diagnostic strategies
  • Differentiate commercial strategies to increase probability of success

Over 100 pharmaceutical, biotech, and medical device firms rely on Flagship’s technology for success. As the largest clinical tissue-image-analysis operation in the US, Flagship has completed over 400 projects since 2009.



Spotlight Partner

At Quansys Biosciences, our teams build and develop customizable multiplex and singleplex assay technologies that allow pharmaceutical companies, clinical laboratories, government institutions, universities and academics around the world access to large amounts of quantitative data quickly and efficiently.

Quansys’s proprietary Q-Plex Array Technology makes it possible to measure up to 22 analytes at one time without compromising assay performance. Quick read times, customization, and highly sensitive assays help researchers to better understand disease and improve their biological sample testing.

Quansys Biosciences was founded by Dr. Rex S. Spendlove in 2005. Dr. Spendlove is also the founder the one of the world leaders in cell culture media, Hyclone Laboratories, now a part of the GE Healthcare and Thermo Fisher Scientific families.



Spotlight Partner

Randox Biosciences are a highly innovative global leader in clinical diagnostic manufacturing supplying the world’s top CRO’s and biopharmaceutical companies. We have technical expertise in diagnostic and CDx assay development utilising single analyte assays, as well as multiplex assays that test up to 23 biomarkers using one patient sample via our Evidence range of analysers. This utilises our proprietary Biochip Array Technology which was developed using our in house range of antibodies, proteins and conjugates. We also offer a custom development service for all our raw materials for the biopharmaceutical and diagnostic industries. As well as custom assay development, our custom services also include polyclonal and monoclonal development and recombinant antibody fragments (sdAb, scFv, Fab).



Spotlight Partner

Genomenon provides immediate insight into the published genomic research for every disease, gene, and mutation found in the scientific literature. Pharmaceutical and biotech companies license Genomenon’s comprehensive genomic landscape on any given disease to identify and prioritize genomic biomarkers for drug discovery and clinical trial targets



Spotlight Partner


ARcher Dx

Spotlight Partner